- Today
- Holidays
- Birthdays
- Reminders
- Cities
- Atlanta
- Austin
- Baltimore
- Berwyn
- Beverly Hills
- Birmingham
- Boston
- Brooklyn
- Buffalo
- Charlotte
- Chicago
- Cincinnati
- Cleveland
- Columbus
- Dallas
- Denver
- Detroit
- Fort Worth
- Houston
- Indianapolis
- Knoxville
- Las Vegas
- Los Angeles
- Louisville
- Madison
- Memphis
- Miami
- Milwaukee
- Minneapolis
- Nashville
- New Orleans
- New York
- Omaha
- Orlando
- Philadelphia
- Phoenix
- Pittsburgh
- Portland
- Raleigh
- Richmond
- Rutherford
- Sacramento
- Salt Lake City
- San Antonio
- San Diego
- San Francisco
- San Jose
- Seattle
- Tampa
- Tucson
- Washington
North Chicago Today
By the People, for the People
Berry Wealth Group LP Cuts Stake in AbbVie Inc.
Institutional investor reduces holdings in pharmaceutical company by 91%
Published on Mar. 6, 2026
Got story updates? Submit your updates here. ›
Berry Wealth Group LP, an institutional investor, has reduced its holdings in AbbVie Inc. (NYSE:ABBV) by 91% in the third quarter, according to a recent disclosure with the Securities and Exchange Commission (SEC). The firm now owns 1,507 shares of the company's stock, down from 16,804 shares previously.
Why it matters
This move by Berry Wealth Group LP reflects broader shifts in institutional investor sentiment around AbbVie. As a major pharmaceutical company, AbbVie's stock performance and ownership changes can provide insights into the broader healthcare and biotech sectors.
The details
According to the SEC filing, Berry Wealth Group LP sold 15,297 shares of AbbVie stock during the third quarter. The firm's remaining 1,507 shares were valued at $349,000 as of the most recent filing. AbbVie accounts for 1.1% of Berry Wealth Group LP's investment portfolio, making it the 21st largest position.
- Berry Wealth Group LP reduced its AbbVie holdings in the third quarter of 2026.
The players
Berry Wealth Group LP
An institutional investor that has reduced its stake in pharmaceutical company AbbVie Inc.
AbbVie Inc.
A global, research-driven biopharmaceutical company that focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions.
The takeaway
This filing highlights the shifting investment landscape around major pharmaceutical companies like AbbVie. Institutional investors are closely monitoring factors like drug pipelines, regulatory changes, and market competition when determining their portfolio allocations in the healthcare sector.
